Premium
Identification of a Novel CD8+ T Cell Epitope Derived from Cancer‐Testis Antigen MAGE‐4 in Oesophageal Carcinoma
Author(s) -
Wu Z. Y.,
Gao Y. F.,
Wu Y. H.,
Liu W.,
Sun M.,
Zhai M. X.,
Qi Y. M.,
Ye Y.
Publication year - 2011
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.2011.02606.x
Subject(s) - epitope , elispot , cytotoxic t cell , cancer immunotherapy , immunotherapy , antigen , cancer research , cd8 , cytotoxicity , biology , microbiology and biotechnology , peptide , cancer , immunology , immune system , biochemistry , in vitro , genetics
MAGE‐4 is considered as an attractive cancer‐testis (CT) antigen for tumour immunotherapy, and it is overexpressed in oesophageal carcinoma (EC). To identify MAGE‐4‐derived HLA‐A2 restricted epitopes, native peptides and their analogues were predicted with prediction programs. The native peptide, p286 (KVLEHVVRV), and its analogues, p286‐1Y2L and p286‐1Y2L9L, showed potent binding affinity and stability towards HLA‐A*0201 molecule. Cytotoxic T lymphocytes (CTLs) induced by p286‐1Y2L9L could release IFN‐γ in ELISPOT assay. In cytotoxicity assay, p286‐1Y2L9L showed the capability to induce specific CTLs which could lyse the target cancer cells from both PBMCs of healthy donors and HLA‐A2.1/K b transgenic mice. Our results indicated that the peptide p286‐1Y2L9L could serve as a novel candidate epitope to develop peptide vaccines against oesophageal carcinoma.